BI 3031185

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for BI 3031185, covering 2024-11-13 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder [Phase 1]

See pricing